Comparative Effectiveness of Tirzepatide and Semaglutide in Individuals at Cardiovascular Risk

NCT07096063 · Completed

Last updated 2026-05-28

This clinical trial compares the effects of tirzepatide and semaglutide on heart-related outcomes in adults with type 2 diabetes who are also overweight or at high risk for cardiovascular disease.

Status Completed The study has finished.

Type Observational

Participants 887,132 people

Who can join Ages 18+ · all sexes

Timeline Started 2024-10 · est. completion 2025-07

Where 1 site · United States

What this study is testing ClinicalTrials.gov NCT07096063 ↗

Description as written by the study sponsor.

Investigators are building an empirical evidence base for real-world data through large-scale emulation of randomized controlled trials. The investigators' goal is to understand for what types of clinical questions real world data analyses can be conducted with confidence and how to implement such studies.

Treatments tested

Tirzepatide Drug

New use of tirzepatide dispensing claim is used as the exposure.
Dulaglutide Drug

New use of dulaglutide dispensing claim is used as the comparator.
Semaglutide Drug

New use of semaglutide dispensing claim is used as the exposure/comparator.
Sitagliptin Drug

New use of sitagliptin dispensing claim is used as the comparator.

Main thing measured	Composite of all-cause mortality, myocardial infarction or stroke (Tirzepatide vs. dulaglutide)
Sponsor	Brigham and Women's Hospital
Conditions studied	Type 2 Diabetes, Overweight, Cardiovascular (CV) Risk
GLP-1 drugs	semaglutide, tirzepatide

Full protocol, eligibility, and contacts on ClinicalTrials.gov NCT07096063 ↗